The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk ...
GlobalData on MSN5d
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatmentUroGen Pharma has received the new drug application (NDA) acceptance from the US Food and Drug Administration (FDA) for ...
A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of ...
UroGen Pharma new drug application for UGN-102, an investigational drug to treat certain types of bladder cancer, was approved by Food and Drug Administration. The company said on Tuesday that UGN-102 ...
The NDA has been accepted for UGN-102 for intravesical solution for low-grade intermediate-risk non-muscle invasive bladder cancer.
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...
PDUFA goal date set for June 13, 2025 UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved "The FDA acceptance of our NDA is a pivotal moment in our journey to bring UGN ...
UroGen Pharma new drug application for UGN-102, an investigational drug to treat certain types of bladder cancer, was approved by Food and Drug Administration. The company said on Tuesday that UGN ...
UroGen Pharma has received the new drug application (NDA) acceptance from the US Food and Drug Administration (FDA) for UGN-102 (mitomycin) for intravesical [directly into the bladder ...
PDUFA goal date set for June 13, 2025 UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and ...
(RTTNews) - UroGen Pharma Ltd. (URGN) said that the U.S. Food and Drug Administration accepted the New Drug Application or NDA for investigational drug UGN-102 (mitomycin) for intravesical solution.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback